Broken out by business line, RTI Biologics saw a 7 percent revenue increase for sports medicine ($11.8 million), a 5 percent revenue increase for surgical specialties ($7.9 million) and a 13 percent revenue increase for bone graft substitutes and general orthopedics ($7.9 million).
More Articles on Orthopedic Devices:
New Instrumentation & Partnership for DePuy Synthes Spine
DePuy Synthes Spine Launches Minimally Invasive Posterior-Lateral Fusion System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.